中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 1
Jan.  2018
Turn off MathJax
Article Contents

Clinical effect of probiotics in treatment of liver cirrhosis: a Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2018.01.015
Research funding:

 

  • Published Date: 2018-01-20
  • Objective To investigate the clinical effect of probiotics in the treatment of liver cirrhosis through a systematic review. Methods PubMed, Embase, Cochrane Library, Chinese Scientific Journal Full-Text Database, VIP, and Wanfang Data were searched for randomized controlled trials ( RCTs) of probiotics for the treatment of liver cirrhosis. Rev Man 5. 3 software was used for the meta-analysis of the articles screened out. Rate difference ( RD) and its 95% confidence interval ( 95% CI) were used as effect size indicators for binary variables; weighted mean difference ( WMD) was used for evaluating continuous variables with the same unit, and standardized mean difference ( SMD) and its 95% CI were used for evaluating continuous variables with different units. Funnel plots were used to analyze publication bias.Results A total of 15 RCTs which met the inclusion criteria were included, and there were 1411 patients with liver cirrhosis in total ( 726 in treatment group and 685 in control group) . Compared with the control group, the treatment group had significant improvements in overall response rate ( RD = 0. 28, 95% CI: 0. 22-0. 34, P < 0. 001) and biochemical parameters for liver function including alanine aminotransferase ( SMD =-0. 90, 95% CI:-1. 14 to-0. 66, P < 0. 001) , total bilirubin ( WMD =-15. 99, 95% CI:-26. 42 to-5. 57, P <0. 001) , albumin ( SMD = 0. 66, 95% CI: 0. 40-0. 93, P < 0. 001) , endotoxin ( SMD =-1. 13, 95% CI:-2. 11 to-0. 15, P <0. 001) , and blood ammonia ( WMD =-15. 86, 95% CI:-21. 54 to-10. 18, P < 0. 001) . Conclusion Probiotics can significantly improve liver function in patients with liver cirrhosis, effectively inhibit the progression of liver cirrhosis, reduce the risk of complications including hepatic encephalopathy, and increase overall response rate and have good tolerability.

     

  • loading
  • [1]LI F, LI ZL, LIN BL, et al.Study on variation of lipidemia and apolipoprotein in posthepatitic cirrhosis and biliary cirrhosis[J].China J Modern Med, 2004, 14 (13) :52-54. (in Chinese) 黎芳, 黎志良, 林炳亮, 等.病毒性肝炎肝硬化与胆汁性肝硬化的血脂及载脂蛋白分析比较[J].中国现代医学杂志, 2004, 14 (13) :52-54.
    [2]BIAN XP, JING JX.Clinical observation of treating hepatocirrhosis diahrrhea with micro-ecological production Miya-BM[J].Natl Med Front China, 2012, 7 (23) :31-32. (in Chinese) 卞孝平, 荆军祥.微生态制剂米雅治疗肝硬化腹泻临床观察[J].中国医疗前沿, 2012, 7 (23) :31-32.
    [3]CHEN YP, ZHONG ZH, LIANG YH, et al.Effect of microbial ecological agent on the function of intestinal mucosa barrier in cirrhosis patients[J].Chin J Clin Gastroenterol, 2010, 22 (4) :204-207. (in Chinese) 陈渝萍, 钟转华, 梁月环, 等.微生态制剂对肝硬化患者肠屏障功能影响及疗效观察[J].临床消化病杂志, 2010, 22 (4) :204-207.
    [4]PEREG D, KOTLIROFF A, GADOTH N, et al.Probiotics for patients with compensated liver cirrhosis:a double-blind placebocontrolled study[J].Nutrition, 2011, 27:177-181.
    [5]DING GW, GAO CG.Clinical efficacy of Saccharomyces boulardii in treatment of diarrhea in patients with liver cirrhosis[J].Guide China Med, 2012, 10 (31) :243-244. (in Chinese) 丁光伟, 高春耕.布拉酵母菌治疗肝硬化腹泻的临床观察[J].中国医药指南, 2012, 10 (31) :243-244.
    [6]FENG ZP, YE WS.Clinical observation of treating hepatocirrhosis diahrrhea with micro-ecological production P.O.Bifidobiogcn[J].J Trop Med, 2002, 2 (1) :52-53. (in Chinese) 冯正平, 叶伟生.微生态制剂丽珠肠乐治疗肝硬化腹泻临床观察[J].热带医学杂志, 2002, 2 (1) :52-53.
    [7]BAJAJ JS, HEUMAN DM, HYLEMON PB, et al.Randomised clinical trial:Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J].Aliment Pharmacol Ther, 2014, 39 (10) :1113-1125.
    [8]PANG CH.Efficacy of oral MIYA-BM tablets in treatment of non-infectious diarrhea in patients with liver cirrhosis[J].Strait Pharm J, 2012, 24 (12) :170-171. (in Chinese) 庞春红.口服米雅BM片治疗肝硬化非感染性腹泻的疗效观察[J].海峡药学, 2012, 24 (12) :170-171.
    [9]SUN XH.The effects of probiotics on intestinal flora and cell-mediated immune function in patients with liver cirrhosis[J].China Mod Doct, 49 (18) :1-2, 11. (in Chinese) 孙晓晖.微生态制剂对肝硬化患者肠道菌群与细胞免疫功能的影响[J].中国现代医生, 49 (18) :1-2, 11.
    [10]WAN W, ZHANG WL, ZHAO J.Influence to serum endotoxin and TNF-αin cirrhosis patients with beifeida therapy[J].J Clin Hepatol, 2005, 21 (2) :93-94. (in Chinese) 万巍, 张薇莉, 赵隽.贝飞达对肝硬化患者血浆内毒素及TNF-α的影响[J].临床肝胆病杂志, 2005, 21 (2) :93-94.
    [11]WANG J, WANG ZY.Medilac-S in treatment of liver cirrhosis combined with spontaneous bacterial peritonitis[J].Occupation Health, 2008, 24 (23) :2610-2611. (in Chinese) 王静, 王震宇.美常安治疗肝硬化并自发性腹膜炎[J].职业与健康, 2008, 24 (23) :2610-2611.
    [12]WANG XL.Efficacy of Bifidobacterium tetravaccine tablets in treatment of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].Chin J Clin Ration Drug Use, 2011, 4 (3A) :49-50. (in Chinese) 王秀丽.双歧杆菌四联活菌片治疗肝硬化自发性细菌性腹膜炎的疗效观察[J].临床合理用药杂志, 2011, 4 (3A) :49-50.
    [13]YANG FT.Efficacy of probiotic preparation in treatment of liver cirrhosis[J].Clin Res Pract, 2016, 1 (20) :80-81. (in Chinese) 杨飞童.益生菌抑剂治疗肝硬化的观察[J].临床医学研究与实践, 2016, 1 (20) :80-81.
    [14]ZHANG BJ, NIU XF, WANG QZ.Efficacy of Golden Bifid in treatment of liver cirrhosis with spontaneous peritonitis[J].J Medical Forum, 2007, 28 (24) :107-111. (in Chinese) 张帮杰, 牛秀峰, 王庆治.金双歧治疗肝硬化并自发性腹膜炎[J].医药论坛杂志, 2007, 28 (24) :107-111.
    [15]ZHAO JM, HU RX, ZHU Q.Efficacy of microecologics in treatment of diarrhea in patients with liver cirrhosis:a report of 56 cases[J].J Clin Med Pract, 2010, 14 (1) :67-70. (in Chinese) 赵坚敏, 胡荣昕, 朱琦.微生态制剂治疗肝硬化腹泻56例临床观察[J].实用临床医药杂志, 2010, 14 (1) :67-70.
    [16]ZHENG SJ, WANG CH, ZHAN GQ.Efficacy of microbioecologics in hepatic cirrhosis patients with spontaneous bacterial peritonitis[J].Chin J Microecol, 2014, 26 (1) :62-65. (in Chinese) 郑三菊, 王崇慧, 占国清.微生态制剂治疗肝硬化自发性细菌性腹膜炎疗效观察[J].中国微生态学杂志, 2014, 26 (1) :62-65.
    [17]DHIMAN RK, RANA B, AGRAWAL S, et al.Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis:a randomized, controlled trial[J].Gastroenterology, 2014, 147 (6) :1327-1337.
    [18]LUNIA MK, SHARMA BC, SHARMA P, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis:a randomized controlled trial[J].Clin Gastroenterol Hepatol, 2014, 12 (6) :1003-1008.
    [19]AGRAWAL A, SHARMA BC, SHARMA P, et al.Secondary prophylaxis of hepatic encephalopathy in cirrhosis:an open-label, randomized controlled trial of lactulose, probiotics, and no therapy[J].Am J Gastroenterol, 2012, 107 (7) :1043-1050.
    [20]WEI X, YAN XB, ZOU DY, et al.Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J].BMC Gastroenterlogy, 2013, 13:175.
    [21]ZHANG SR.Curative effects of probiotics combined with adefovir dipivoxil in treatment of HBV-related cirrhosis and the effects on immune function[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :44-47. (in Chinese) 张世睿.微生态制剂联合阿德福韦酯治疗慢性乙型肝炎肝硬化的疗效及对机体免疫功能的影响[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :44-47.
    [22]BAJAJ JS, RIDLON JM, HYLEMON PB, et al.Linkage of gut microbiome with cognition in hepatic encephalopathy[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302 (1) :g168-g175.
    [23]PANDE C, KUMAR A, SARIN SK.Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis:a double-blind placebo-controlled randomized-controlled trial[J].Eur J Gastroenterol Hepatol, 2012, 24 (7) :831-839.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1869) PDF downloads(490) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return